The Effectiveness of Herbal Remedies as Therapeutic and Preventive Measures for Cystitis in Children

Cover Page

Cite item

Full Text

Abstract

The study included 88 children aged from 1 to 14 years (Iu = 7.5 years) with dysuric disorders in whom the diagnosis of cystitis was confirmed endoscopically. The main group consisted of 46 children who received the herbal medicinal product Canephron N as monotherapy for acute manifestations of the disease, as well as a preventive measure for 6 months. The control group included 42 children on antibiotic therapy and without preventive measures. The sufficiency of the herbal drug for relieving the symptoms of the disease was noted, as well as a significant decrease in the probability of total relapses (p=0.005), especially exacerbations of cystitis (p=0.041), including those of a recurrent nature (p=0.038). The advantages of Canephron N were also considered based on a comparative assessment of the dynamics of the urine microflora in the acute period and during exacerbations in catamnestic observation. The results obtained indicate the expediency of using Canephron N in children with cystitis for therapeutic and preventive purposes.

About the authors

V. I. Kirillov

Federal State Budgetary Educational Institution of Higher Education Russian University of Medicine of the Ministry of Health of the Russian Federation

Email: msmsu@msmsu.ru
MD, PhD, professor, pediatrics teacher, carries out research and consulting activities at the nephrology department 127006, Russia, Moscow, Dolgorukovskaya str., 4

N. A. Bogdanova

Federal State Budgetary Educational Institution of Higher Education Russian University of Medicine of the Ministry of Health of the Russian Federation

Email: msmsu@msmsu.ru
MD, PhD, associate professor, pediatrics teacher, carries out research and consulting activities at the nephrology department 127006, Russia, Moscow, Dolgorukovskaya str., 4

References

  1. Warren J. W. et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Dseases Society of America (IDSA). Clin. Infect Dis 1999; 162: 41–47.
  2. Grabe M. et al. Guidelines on Urological Infections. Europan Association of Urology. 2015.
  3. Лопаткин Н. А., Пугачёв А. Г. Детская урология. Руководcтво. Москва. «Медицина». 1968. — 493 с. [ Lopatkin N. A., Pugachev A. G. Pediatric urology. Guide. — M.: «Medicine». 1968: 493. (In Russ.)].
  4. Клинические рекомендации МЗ РФ (КР 281). Инфекция мочевыводящих путей у детей. 2021. Рубрикатор КР (minzdrav.gov.ru). [Clinical recommendations of the Ministry of Health of the Russian Federation (KR 281). Urinary tract infection in children. 2021. The category of the KR (minzdrav.gov.ru) (In Russ.)].
  5. Okarska-­Napierata M., Wasilewska A., Kuchar E. UTI in children: diagnosis, treatment. imaging — comparison of current guidelines. J. Pediatr. Urol. 2017; 13 (6): 567–573.
  6. Возрастающая угроза антимикробной резистентности. Возможные меры. ВОЗ 2013. http://apps.who.int/iris/bitstream/10665/44812/16/9789244503188_rus.pdf [The increasing threat of antimicrobial resistance. Possible measures. WHO 2013. (In Russ.)]. http://apps.who.int/iris/bitstream/10665/44812/16/9789244503188_rus.pdf
  7. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М., 2017. [Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal Clinical Guidelines. M., 2017. (In Russ.)].
  8. Палагин И. С. Современные аспекты выбора антимикробных препаратов при острых неoсложненных циститах. Клин. микроб и антимикробные химеопрепараты. 2009; 11 (4): 327–334. [Palagin I. S. Modern aspects of the choice of antimicrobial drugs in acute uncomplicated cystitis. The wedge. microbe and antimicrobial chemotherapy drugs. 2009; 11 (4): 327–334. (In Russ.)].
  9. Stein R., Dogan H. S., Hoebeke P., Kocvara R., Nijman R. J., Radmayr C. Urinary tract infections in children: EAU/ESPU Guidelines. European urology. 2015; 67: 546–558.
  10. Кириллов В. И., Богданова Н. А., Морозов С. Л. Неантибактериальные альтернативные мероприятия при инфекции мочевых путей у детей. Часть 1. Подавление микробной инициации воспаления. Рос. вестн. перинатологии и педиатрии. 2018; 63 (1): 106–112. [Kirillov V. I., Bogdanova N. A., Morozov S. L. Non-antibacterial alternative measures for urinary tract infection in children. Part 1. Suppression of microbial initiation of inflammation. Ros. vestn. perinatology and pediatrics. 2018; 63 (1): 106–112. (In Russ.)].
  11. Кириллов В. И., Богданова Н. А., Морозов С. Л., Неантибактериальные альтернативные мероприятия при инфекции мочевых путей у детей. Часть 2. Подавление микробной инициации воспаления// Рос. вестн. перинатологии и педиатрии. 2018; 63 (4): 113–118. (In Russ.)]. [Kirillov V. I., Bogdanova N. A., Morozov S. L., Non-antibacterial alternative measures for urinary tract infection in children. Part 2. Suppression of microbial initiation of inflammation. Ross. vestn. perinatology and pediatrics. 2018; 63 (4): 113–118. (In Russ.)].
  12. Gesellchaft fur Padiatrische Nephrologie und Arbeitskreis Kinder — und Jugendurologie der Deutschen Gesellshaft fur Urologie: Interdisziplinare S2k-­Leitlinie: Harnwegsinfektionen im kindesalter: Diagnostik, Therapie und Prophylaxe. Version 1. 2021; 23: 08.
  13. Пыриг Л. А., Мельман Н. Я. Антибактериальная терапия в нефрологии. ВКН: антибактериальная терапия в урологии и нефрологии. Ред. В. С. Карпенко. Киев: «Здоров’я». 1979: 42–152. [Pyrig L. A., Melman N. Ya. Antibacterial therapy in nephrology. In the BOOK: antibacterial therapy in urology and nephrology. Ed. V. S. Karpenko. Kiev: Zdorov’ya. 1979: 142–152. (In Russ.)].
  14. Davidov M. L., Bunova N. E. Comparative assessment of Canephron N and a сiprofloxacin as monotherapy of acute un complicated cystitis in women. Urologia. 2018 (4): 24–32.
  15. Кириллов В. И., Богданова Н. А. Эффективность альтернативных методов лечения инфекций мочевыводящих путей в педиатрической практике и принцип минимальной достаточности антибактериальной терапии. Практика педиатра. 2022; (4): 42–49. [Kirillov V. I., Bogdanova N. A. Effectiveness of alternative methods of treatment of urinary tract infections in pediatric practice and the principle of minimum sufficiency of antibacterial therapy. Practice of pediatrician. 2022; (4): 42–49. (In Russ.)].
  16. Christiaenes T. C. et al. Randomised controlled triael of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br. J. Gen. Pract. 2020; 52: 729–734.
  17. Bleidorn J. et al. Symptomatic treatment (ibuprofen) urn antibiotics (cipro-­floxacin) for uncomplicated urinary tract infection? Results of randomized controlled pilot trial. BMC Medicine. 2010. 8: 30–37.
  18. Italia S., Wolfenstetter S. B., Teuner C. M. Patterns of complementary and alternative medicine (CAM) use in children: asystematic review. Eur J. Pediatr. 2014; (173): 1413–1428.
  19. Резолюция совета экспертов по вопросу применения растительных лекарственных препаратов при инфекциях мочевыводящих путей у детей (Бионорика). Рос. вест. перинатал. pediatric. 2023; 68 (5): 147–149. [Resolution of the Council of Experts on the use of herbal medicines for urinary tract infections in children (Bionorica). Russian West. perinatal. pediatric. 2023; 68 (5): 147–149. (In Russ.)].
  20. Dlin V. V. et al. A non-interventional, prospective, multicenter study for evalugtion of the use herbal medical product Canephron N in the pediatric outpatient population in Russia. Clin. Phytoscience. 2018; 4: 31–34.
  21. Ivanov P. et al. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron N in the management of uncomplicated urinary tract infections. Clin. Phytoscience 2015; 1: 724.
  22. Кальтянис П. А., Бачюлис В. П. Результаты исследования покрытых антителами бактерий в моче детей с инфекцией мочевой системы. Симпозиум «Хронический пиелонефрит у детей» тезисы докладов. — М., 1980: 79–80. [Kaltianis P. A., Bachyulis V. P. Results of a study of antibody-­coated bacteria in the urine of children with urinary tract infection. Symposium “Chronic pyelonephritis in children” abstracts. — M., 1980: 79–80. (In Russ.)].
  23. Garin E. N., Campos A., Homsy Y. Primary vesicouereteral reflux: review of current concepts. Pediatr. Nephrol. 1998; 12 (2): 249–256.
  24. Alidjanov J. F. et al. New self-reporting questoinnaire to assess urinary tract infections and differental diagnosis urinary tract infections and differential diagnosis: acute cystits simptom score. Urologia Internationalis. 2014; 92: 230–236.
  25. Вялкова А. А. и др. Oбоснование клинико-­микробиологических подходов к лечению и профилактике рецидивов пиелонефрита у детей. Педиатр. Фармакол. 2009; 6 (20): 94–98. [Vyalkova A. A. et al. Substantiation of clinical and microbiological approaches to the treatment and prevention of recurrent pyelonephritis in children// Pediatrician. Pharmacol. 2009; 6 (20): 94–98. . (In Russ.)].
  26. Mohseni M. J., Aryan Z., Emamzadeh-Fard S., Paydary K., Mufid V., Joudari H., Kajbedzader A. M. Combination of probiotics and antibiotics in the prevention of recurrent urinary tract infection in children. Iran J. Pediatr. 2013; 23 (4): 430–438.
  27. Зоркин С. Н. и др. Опыт использования препарата уро-ваксом при осложненных инфекциях мочевых путей у детей. Эффективная фармакотерапия. Педиатрия, 2014, 16 (2): 40–42. [Zorkin S. N. et al. Experience of using the drug uro-wax in complicated urinary tract infections in children. Effective pharmacotherapy. Pediatrics, 2014, 16 (2): 40–42. (In Russ.)].
  28. Naber K. G. Efficacy and safety of the phitotherapeutic drug Canephron in prevention and treatment of urogenatal and gestation disease: review of clinacal experience in Eastern Europe and Central Asia. Rec Rep Urol. 2013; 5: 39–46.
  29. Кириллов В. И., Богданова Н. А. Клинико-­патогенетическое обоснование эффективности растительного препарата Канефрон Н в нефрологии детского возраста. РМЖ. 2016; 28: 841–846. [Kirillov V. I., Bogdanova N. A. Clinical and pathogenetic substantiation of the effectiveness of the herbal preparation Kanefron N. in pediatric nephrology. RMZH. 2016; 28: 841–846. (In Russ.)].
  30. Колесник Н. и др. Прорецидивные особенности бактериальной резистентности у больных с неосложненной инфекцией мочевой системы. Tезисы IV Конгресса ассоциации нефрологов новых независимых государств. Минск, 2016: 58–60. [Kolesnik N. et al. Recurrent features of bacterial resistance in patients with uncomplicated urinary system infection. Abstracts of the IV Congress of the Association of Nephrologists of the Newly Independent States. Minsk. 2016; 58–60. (In Russ.)].
  31. Mannhardt W. et al. Host defense within the urinary tract. I. Bacterial adhesion initiates an uroepithelial difense mechanism. Pediatr. Nephrol. 1996; 10 (2): 568–572.
  32. Karoly E. et al. Heat shock protein 72 (HSPA 18) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Pediatr Res. 2007; 61: 371–374.
  33. Zhao R., Zhou H., Su S. B. A critical role for interleukin — 1 beta in the progression of autoimmune diseases. Int. Immunopharmacol. 2013; 17 (3): 658–669.
  34. Beetz R. May we go on with antibacterial prophylaxis for urinary tract infection? Pediatr. Nephrol. 2006; 21 (1): 5–13.
  35. Mattoo T. K. Evidence for and against urinary prophylaxis in vesicoureteral reflux. Pediatr. Nephrol. 2010; 26 (4): 2379–2382.
  36. Богданова Н. А., Кириллов В. И., Никитина С. Ю. Эффективность протоколов лечения острого пиелонефрита у детей с использованием растительных и иммуннотропных препаратов. Материалы V Росс. конгресса по детской нефрологии. Воронеж. 2006: 35–37. [Bogdanova N. A., Kirillov V. I., Nikitina S. Yu. Effectiveness of protocols for the treatment of acute pyelonephritis in children using herbal and immunotropic drugs. Materials V. ross. Congress on Pediatric Neurology. Voronezh. 2006: 35–37. (In Russ.)].
  37. Naber K. et al. Non-antibiotic herbal therapy of uncomplicated lower urinary tract infections in women — a pilot study (Abstr.). Planta Medica 2013; 79: 1140.
  38. Козлов З. С. Проблема антибиотикорезистентности в педиатрии. РМЖ. 2014; 3: 238–239.[Kozlov Z. S. The problem of antibiotic resistance in pediatrics. RMJ. 2014; 3: 238–239. (In Russ.)].
  39. Breinbjerg A. et al. Risk factors for kidney scarring and vesicoureteral reflux in 421 children after their first acute pyelonephritis and appraisal of international guidines. Pediatr. Nephrol. 2021; 36: 2777–2787.
  40. Hansson S. et al.Untreated asymptomatic bacteruria in girls. Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infection. BMJ; 1989; 298: 856–859.
  41. Wullt B., Svanborg C. Deliberate establishment of asymptomatic bacteriuria — a novel strategy prevent recurrent UTL. Pathogens. 2016; 5 (3): 52–58.
  42. Cheng C.-H. et al. Comparison of extended Virulence genotypes for bacteria isolated from pediatric patients with uposepsis, acute pylonyphritis and acute lobar nephronia. Pediatr. Infect. Dis Journal. 2010; 29 (8): 736–740.
  43. Эрман М. В. Фитотерапия в лечении инфекции мочевой системы у детей. Эффективная фармакотерапия. Педиатрия. 2014; 16 (2): 16–22. [Erman M. V. Phytotherapy in the treatment of urinary system infection in children. Effective pharmacotherapy. Pediatrics. 2014; 16 (2): 16–22. (In Russ.)].
  44. Gessner A. The influence of urologic therapeutics on the microbiome in an experimental model. (Abstr). 31st Annual EAU Congress. Munich. 2016; 52.
  45. Аполихина И. А., Малышкина Д. А. Хронические рецидивирующие циститы: современные подходы к лечению. Медицинский оппонент. 2020; 2 (10): 30–34 [Apolikhina I. A., Malyshkina D. A. Chronic recurrent cystitis: modern approaches to treatment. Meditsinskiy opponent=Medical opponent. 2020; 2 (10): 30–34. (In Russ.)].- https://proffopponent.ru/meditsinskie-­publikacii/2–2020/
  46. Кириллов В. И., Богданова Н. А. Инфекция мочевой системы: проблемы остаются. Медицинский оппонент. 2020; 4 (12): 61–64. [Kirillov V. I., Bogdanova N. A. Urinary tract infection: problems remain. Meditsinskiy opponent=Medical opponent. 2020; 4 (12): 61–64. (In Russ.)].- https://proffopponent.ru/2021/02/11/infekcija-­mochevoj-sistemy-­problemy-ostajutsja/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).